Press release
Keros Therapeutics to Present at the 27th Annual Congress of the European Hematology Association
LEXINGTON, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need today announced that three abstracts will be presented from the KER-050 and ALK2 hematology programs at the 27th Annual Congress of the European Hematology Association (“EHA”), to be held both virtually and in person from June 9-17, 2022. The following abstracts were posted to the EHA website on May 12, 2022, 10:00 a.m. Eastern time. Clinical Presentation “A Phase 2, open-label, ascending dose study of KER-050 for the treatment of anemia in patients with very low, low, or intermediate risk myelodysplastic syndromes” Abstract Code: P776Session Title: Poster sessionSession Date and Time: Friday, June 10, 2022 – 10:30 am to 11:45 am Eastern time Preclinical Presentations “RKER-050, a novel inhibitor of TGF-β superfamily signaling, induced platelet production in healthy mouse megakaryocytes” Abstract Code: P1410Session Title: Poster sessionSession Date and Time: Friday, June 10, 2022 – 10:30 am to 11:45 am Eastern time “ALK2 inhibition lowered hepcidin and liberated spleen iron for erythropoiesis in anemia of inflammation” Abstract Code: P1567Session Title: Poster sessionSession Date and Time: Friday, June 10, 2022 – 10:30 am to 11:45 am Eastern time About KER-050 Keros’ lead protein therapeutic product candidate, KER-050, is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta receptor known as activin receptor type IIA that is fused to the portion of the human antibody known as the Fc domain. KER-050 is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. About Keros Therapeutics, Inc. Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros is a leader in understanding the role of the transforming growth factor-beta family of pro...